BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial ... PharmiWeb.com (press release) Pre-clinical studies show that BL-8040 is efficient both alone and in combination with the anti-cancer drug Rituximab in reducing bone marrow metastasis of lymphoma cells and stimulating lymphoma cell death. BL-8040 was licensed by BioLineRx from ... |
